Back

David P. Hudesman, shares insight on long-term extension data and clinical implications from ACG 2022 on the use of ustekinumab for the management of ulcerative colitis.

Four-Year Efficacy and Safety Data of Ustekinumab Use in Ulcerative Colitis

Episodes

Specialty:

All

Year:

All

EP. 1: Management of Relapsing Ulcerative Colitis

ByDavid P. Hudesman, MD

November 22nd 2022

David P. Hudesman, MD, provides insight on approaching induction therapy and maintenance therapy for patients with relapsing ulcerative colitis.

EP. 2: ACG 2022 Data on Ustekinumab Durability for Ulcerative Colitis

ByDavid P. Hudesman, MD

November 22nd 2022

David P. Hudesman, MD, reviews data presented at the ACG 2022 Annual Scientific Meeting on the safety and efficacy of ustekinumab for ulcerative colitis treatment.

EP. 3: ACG 2022 Data on Corticosteroid-Sparing Effects of Ustekinumab for Ulcerative Colitis

ByDavid P. Hudesman, MD

November 29th 2022

David P. Hudesman, MD, reviews long-term extension study data for the corticosteroid-sparing effects of ustekinumab on ulcerative colitis as presented at ACG 2022.

EP. 4: Clinical Implications of Ustekinumab in Ulcerative Colitis Treatment

ByDavid P. Hudesman, MD

November 29th 2022

David P. Hudesman, MD, discusses clinical implications from ACG 2022 data on ustekinumab therapy for the management of ulcerative colitis and shares advice for managing patients with the disease.